| Literature DB >> 27713682 |
Dolores Camacho-Muñoz1, Bruce Petrie1, Erika Castrignanò1, Barbara Kasprzyk-Hordern1.
Abstract
The issue of drug chirality is attracting increasing attention among the scientific community. The phenomenon of chirality has been overlooked in environmental research (environmental occurrence, fate and toxicity) despite the great impact that chiral pharmacologically active compounds (cPACs) can provoke on ecosystems. The aim of this paper is to introduce the topic of chirality and its implications in environmental contamination. Special attention has been paid to the most recent advances in chiral analysis based on liquid chromatography coupled with mass spectrometry and the most popular protein based chiral stationary phases. Several groups of cPACs of environmental relevance, such as illicit drugs, human and veterinary medicines were discussed. The increase in the number of papers published in the area of chiral environmental analysis indicates that researchers are actively pursuing new opportunities to provide better understanding of environmental impacts resulting from the enantiomerism of cPACs.Entities:
Keywords: Analysis; chiral chromatography; chiral drugs; environment; mass spectrometry; pharmaceuticals; wastewater
Year: 2016 PMID: 27713682 PMCID: PMC5024650 DOI: 10.2174/1573411012666151009195039
Source DB: PubMed Journal: Curr Anal Chem ISSN: 1573-4110 Impact factor: 1.892
Fig. (1)Structures of chiral drugs (* denotes chiral centers; MDMA: 3,4-methylenedioxymethamphetamine).
Validated chiral liquid chromatography methods coupled with tandem mass spectrometry for enantiomeric profiling of chiral human pharmaceutical active compounds in environmental matrices.
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Amphetamine, methamphetamine, mephedrone, MDMA, MDA, | Influent wastewater (100 mL) | Grab | Filtration (0.7 µm), Oasis HLB SPE | Chiral-CBH column (100 x 2 mm, 5 µm particle size). 85: 15 H2O: MeOH with 1 mM NH4OAc (pH 6.4) | Triple quadrupole | [ | |
| Ibuprofen, naproxen, ketoprofen, chloramphenicol, ifosfamide, 10,11 dihydrocarbamazepine, fexofenadine, 3-n-dichloroethylifosfamide, dihydroketoprofen, tetramisole, aminorex, praziquantel | Effluent wastewater (250 mL), river water (500 mL) | Grab | Filtration (0.7 µm), Oasis HLB SPE and Oasis MCX | AGP (100 x 2 mm, 5 µm particle size). 99: 1 H2O with 10 mMNH4OAc: ACN pH 6.7 | Triple quadrupole | [ | |
| Amphetamine, methamphetamine, ephedrine/pseudoephedrine, MDA, MDMA, norephedrine, venlafaxine, atenolol,metoprolol, propranolol, mirtazapine, tramadol, desmethylvenlafaxine, desmethylcitalopram, fluoxetine, salbutamol, sotalol, citalopram | Influent wastewater (50 mL), effluent wastewater (50 mL) and digested sludge (1 g) | Grab | Liquid: filtration (0.7 µm), Oasis HLB SPE | Chirobiotic V (250 x 4.6 mm, 5 µm particle size). MeOH with 4 mM NH4OAc, 0.005% formic acid. | Triple quadrupole | 0.1-29ng L-1 influent wastewater, 0.1-11 ng L-1 effluent wastewater, 0.1-113 ng g-1 digested sludge | [ |
| Ibuprofen, ketoprofen, naproxen | Influent wastewater (72.2 mL), effluent wastewater (72.2 mL) | Grab | Microextraction with supramolecular solvent | Sumichiral OA-2500 (250 x 4.6 mm, 5 µm particle size). 90:10 tetrahydrofuran: 50 mM NH4OAc in MeOH | Triple quadrupole/linear ion trap | 0.5-1.2 (MDLs) | [ |
| Fluoxetine, norfluoxetine, venlafaxine, alprenolol, bisoprolol, metoprolol, propranolol, salbutamol | Effluent wastewater (250 mL) | - | Filtration (0.45 µm), Oasis MCX SPE | Chirobiotic V (150 x 2.1 mm, 5 µm particle size). 92.5: 7.5 H2O with 10 mM NH4OAc: ethanol pH 6.8 | Triple quadrupole | 2.0-20 | [ |
| Betaxolol, propranolol, ibuprofen, pindolol, fluoxetine, salbutamol, sotalol, timolol, carazolol, clenbuterol, metoprolol, atenolol | Influent wastewater (100 mL), effluent wastewater (100 mL), river water (500 mL) | Composite (wastewater), grab (river) | Filtration (0.7 µm), Oasis HLB SPE | Chirobiotic V (250 x 4.6 mm, 5 µm particle size). MeOH with 4 mM NH4OAc, 0.005% formic acid. | Triple quadrupole | 0.2-28 ng L-1 influent wastewater, 0.2-28 ng L-1 effluent wastewater, 0.2-9 ng L-1 river water | [ |
| Amphetamine, methamphetamine, MDMA, propranolol, atenolol, metoprolol, venlafaxine, fluoxetine | Effluent wastewater (100 mL), river water (250 mL) | Grab | Filtration (0.7 µm), Oasis HLB SPE | Chirobiotic V (250 x 4.6 mm, 5 µm particle size). MeOH with 4 mM NH4OAc, 0.005% formic acid. Chiral-CBH column (100 x 2 mm, 5 µm particle size). 90: 10 H2O: 2-propanol with 1 mM NH4OAc (pH 5) | Quadrupole time-of-flight | 1.3-86 ng L-1 effluent wastewater, 0.3-39 ng L-1 river water | [ |
| Fluoxetine, norfluoxetine | Influent wastewater (200 mL), effluent wastewater (500 mL) | Grab | pH adjusted to 4, Evolute CX-50 SPE | AGP (100 x 2 mm, 5 µm particle size). 97: 3 H2O with 10 mM HN4OAc: ACN | Triple quadrupole | 0.9-4.3 | [ |
| Norephedrine, ephedrine/pseudoephedrine, amphetamine, methamphetamine, venlafaxine, MDEA, MDMA, MDA, | Influent wastewater (100 mL), effluent wastewater (100 mL) | Grab | Filtration (0.7 µm), Oasis HLB SPE | Chiral-CBH column (100 x 2 mm, 5 µm particle size). 90: 10 H2O: 2-propanol with 1 mM NH4OAc (pH 5) | Triple quadrupole | 2.2-12 ng L-1 influent wastewater, 2.8-10 ng L-1 effluent wastewater | [ |
| Atenolol, metoprolol, pindolol, propranolol, sotalol, citalopram, salbutamol | Influent wastewater (100 mL), effluent wastewater (500 mL) | Grab | Filtration (0.7 µm), Oasis HLB SPE | Chirobiotic V (250 x 4.6 mm, 5 µm particle size). 90: 10 MeOH: H2O with 20 mM NH4OAc, 0.1% formic acid (pH 5) | Triple quadrupole | 1-25 ng L-1 influent wastewater, 0.2-2.5 ng L-1 effluent wastewater | [ |
| Atenolol, metoprolol, propranolol | Influent wastewater (100 mL), effluent wastewater (500 mL) | Grab | Filtration (0.7 µm), Oasis HLB SPE | Chirobiotic V (250 x 4.6 mm, 5 µm particle size). 90: 10MeOH: H2O with 0.1% triethyl ammonium acetate (pH 4) | Triple quadrupole | 17-110 ng L-1 influent wastewater, 4.4-17 ng L-1 effluent wastewater | [ |